

# Performance highlights

## Financial highlights

Revenue	Operating profit	Core <sup>1</sup> operating profit	Profit to shareholders
<b>\$2,875m</b>	<b>\$367m</b>	<b>\$707m</b>	<b>\$190m</b>
<b>+14%</b> 2022: \$2,517m	<b>+30%</b> 2022: \$282m	<b>+19%</b> 2022: \$596m	<b>+1%</b> 2022: \$188m
Core profit to shareholders	Basic earnings per share	Core basic earnings per share <sup>2</sup>	Dividend per share
<b>\$492m</b>	<b>86c</b>	<b>223c</b>	<b>72c</b>
<b>+21%</b> 2022: \$406m	<b>+2%</b> 2022: 84c	<b>+23%</b> 2022: 181c	<b>+29%</b> 2022: 56c

## Non-financial highlights

Value of our donated medicines	Reduction in our Scope 1 and 2 GHG emissions since 2020 <sup>3</sup>
<b>\$4.9m</b>	<b>15%</b>
2022: \$4.3m	2022: 17% <sup>4</sup>

1. Core results are presented to show the underlying performance of the Group, excluding the exceptional items and other adjustments set out in Note 6 of the Group consolidated financial statements. A reconciliation from core to reported operating profit is included within the consolidated income statement in the financial statements
2. Core basic earnings per share is reconciled to basic earnings per share in Note 14 of the Group consolidated financial statements
3. We have committed to reducing Scope 1 and Scope 2 greenhouse gas emissions (market-based) by 25% by 2030, using a 2020 baseline year. Emissions data for this report uses actual data from January to October 2023 and an uplifting exercise to estimate quantities for October to December 2023. See page 50 for further details on our target and our environmental reporting methodology
4. Emissions for 2022 have been restated by +2% as we continue to improve our monitoring and analysis of environmental metrics

## Contents

### Strategic report

What we do .....	2
Executive Chairman's statement .....	4
Chief Executive Officer's statement .....	6
Our strategy .....	10
Our business model .....	12
Investment case .....	14
Our progress .....	16
Our markets .....	18
Stakeholder engagement .....	20

### Business and financial review

Group overview .....	26
Injectables .....	28
Branded .....	30
Generics .....	32
Group performance .....	34

### Sustainability

Acting responsibly at Hikma .....	40
Aligning with the TCFD recommendations .....	56

### Risk management

Risk management .....	68
Going concern and longer-term viability .....	75
Non-financial and sustainability information statement .....	78

### Corporate governance

Executive Chairman's overview .....	82
Corporate governance at a glance .....	84
Board of Directors .....	86
Executive Committee .....	88
UK Corporate Governance Code .....	89
Committee reports .....	94
Annual report on remuneration .....	114
Other statutory disclosures .....	133

### Financial statements

Independent auditors' report .....	140
Consolidated financial statements .....	146
Notes to the consolidated financial statements .....	151
Company financial statements .....	194
Notes to the Company financial statements .....	196

### Shareholder information

Shareholder information .....	201
-------------------------------	-----



For more information visit  
[www.hikma.com](http://www.hikma.com)